Publications by authors named "Helene Parise"

Claim this Profile
B
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Zahra Mahmoudjafari, Jia Li, Eric Bercaw, Hélène Parisé, Katalin Bognar

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Jesse Fishman, Yestle Kim, Hélène Parisé, Eric Bercaw, Zachary Smith

J Med Econ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
Matthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, Eric Zuk, Danilo Di Maio

J Med Econ· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu

Pharmacoeconomics· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
Sang Kyu Cho, Beenish S Manzoor, Kavita R Sail, Hélène Parisé, Arliene Ravelo

Pharmacoeconomics· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia.
Hélène Parise, Robert Espinosa, Katherine Dea, Pablo Anaya, Giovanny Montoya

Pharmacoecon Open· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.
Scott J Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C Samp

J Med Econ· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Sammy Saab, Hélène Parisé, Suchin Virabhak, Alice Wang, Steven E Marx

J Med Econ· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Sammy Saab, Suchin Virabhak, Hélène Parisé, Scott Johnson, Alice Wang

Adv Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes.
Naunihal S Virdi, Patrick Lefebvre, Hélène Parisé, Mei Sheng Duh, Dominic Pilon

J Diabetes Sci Technol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.
Hélène Parisé, François Laliberté, Patrick Lefebvre, Mei Sheng Duh, Edward Kim

J Neurol Sci· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.
Alan H Gradman, Hélène Parisé, Patrick Lefebvre, Heather Falvey, Marie-Hélène Lafeuille

Hypertension· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Ranjani Manjunath, Pierre Emmanuel Paradis, Hélène Parisé, Marie-Hélène Lafeuille, Brian Bowers

Neurology· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis